PMID- 29853297
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20220408
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 12
IP  - 6
DP  - 2018 Dec
TI  - Linagliptin safety profile: A systematic review.
PG  - 477-490
LID - S1751-9918(18)30087-1 [pii]
LID - 10.1016/j.pcd.2018.04.006 [doi]
AB  - OBJECTIVE: To describe the safety profile of linagliptin. METHODOLOGY: Systematic 
      review using PubMed/MEDLINE, BVS and Web of Science. The search strategy 
      "Linagliptin" AND "safety" was used. The inclusion criteria were clinical trials 
      with a control group composed of conventional DM2 pharmacotherapy. RESULTS: We 
      identified 16 studies, and the most frequent adverse events (AEs) were 
      nasopharyngitis with linagliptin at 5 and 10mg in monotherapy (31.6% and 29.6%, 
      respectively) and gastrointestinal events (>10.0%) with linagliptin in 
      combination. Of the AEs, 14.9 (+/-3.1)% were associated with the use of linagliptin 
      in monotherapy, and 17.6 (+/-6.0)% in combination. The linagliptin AEs have a 
      varied occurrence and frequency, ranging from mild to moderate intensity.
CI  - Copyright (c) 2018 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Gomes, Gabrielle Kefrem Alves
AU  - Gomes GKA
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: 
      gabriellekefren@hotmail.com.
FAU - de Camargos Ramos, Aline Istefane
AU  - de Camargos Ramos AI
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: 
      alineistefane@gmail.com.
FAU - de Sousa, Camila Tavares
AU  - de Sousa CT
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: 
      camilatavares.sousa@hotmail.com.
FAU - Sanches, Cristina
AU  - Sanches C
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: csgiraud@ufsj.edu.br.
FAU - Pereira, Mariana Linhares
AU  - Pereira ML
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: 
      marianapereira@ufsj.edu.br.
FAU - Baldoni, Andre Oliveira
AU  - Baldoni AO
AD  - Universidade Federal de Sao Joao del-Rei, Campus Centro Oeste Dona Lindu, Rua 
      Sebastiao Goncalves Coelho, 400, Bairro Chanadour, CEP 35501-296, Divinopolis, 
      MG, Brazil; Grupo de Pesquisa em Epidemiologia e Avaliacao de Novas Tecnologias 
      em Saude, GPEANTS, UFSJ/CNPq, Brazil. Electronic address: 
      andrebaldoni@ufsj.edu.br.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20180528
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Dipeptidyl Peptidase 4/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Linagliptin/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Patient Safety
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Dipeptidyl peptidase 4 (DPP-4) inhibitors
OT  - Gliptins
OT  - Incretins
OT  - Pharmacovigilance
EDAT- 2018/06/02 06:00
MHDA- 2019/04/23 06:00
CRDT- 2018/06/02 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2018/04/24 00:00 [revised]
PHST- 2018/04/25 00:00 [accepted]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
PHST- 2018/06/02 06:00 [entrez]
AID - S1751-9918(18)30087-1 [pii]
AID - 10.1016/j.pcd.2018.04.006 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2018 Dec;12(6):477-490. doi: 10.1016/j.pcd.2018.04.006. Epub 
      2018 May 28.